Novo Nordisk A/S Common Stock (NY:NVO)

37.32 -0.08 (-0.21%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

1 Reason This Biotech Stock Could Triple Before Year-End ↗

March 29, 2026

This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate.

Via The Motley Fool

1 Reason Eli Lilly Stock Is Still a Buy ↗

March 28, 2026

Eli Lilly is much more than just a weight loss stock.

Via The Motley Fool

Topics Artificial Intelligence

Novo Nordisk: A Strong Contender in the Pharmaceutical Arena ↗

March 27, 2026

Could Novo Nordisk be the hidden gem you've been searching for? Join us as we evaluate its current market position and future prospects in this insightful episode.

Via The Motley Fool

Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly

March 27, 2026

INDIANAPOLIS – In a move that has left some retail investors scratching their heads, shares of Eli Lilly and Company (NYSE:LLY) have trended lower this week, despite the pharmaceutical giant releasing...

Via MarketMinute

Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy? ↗

March 27, 2026

It's not much of a contest right now.

Via The Motley Fool

Could Buying Eli Lilly Today Set You Up for Life? ↗

March 26, 2026

Eli Lilly is leading the GLP-1 market, and investors are enthralled with the stock.

Via The Motley Fool

Topics Intellectual Property

What's Happening With Novo Nordisk Stock Today? ↗

March 26, 2026

Novo Nordisk A/S (NYSE:NVO) shares are moving higher on Thursday. Hims & Hers Health Inc (NYSE:HIMS) announced it will begin offering several of the Novo's FDA‑approved GLP‑1 medications, including the...

Via Benzinga

Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss

March 26, 2026

The biotechnology landscape witnessed a defining moment on March 26, 2026, as Wave Life Sciences (Nasdaq: WVE) released highly anticipated interim Phase 1 data from its INLIGHT trial. The study, which...

Via MarketMinute

Kodiak Sciences Surges 19% as Phase 3 GLOW2 Trial Delivers Vital Win for Diabetic Retinopathy Treatment

March 26, 2026

On March 26, 2026, Kodiak Sciences (Nasdaq: KOD) saw its shares ignite, surging 19% in heavy trading following the announcement of overwhelmingly positive topline results from its Phase 3 GLOW2 study....

Via MarketMinute

Surging Oil Prices Spark Market Jitters ↗

March 25, 2026

The Motley Fool's Hidden Gems team discusses some historical disruptions in the energy market, how trends in semiconductors are reshaping the S&P 500, and why Hims & Hers stock is soaring.

Via The Motley Fool

Topics Artificial Intelligence Economy Stocks

The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition

March 25, 2026

On this Wednesday, March 25, 2026, the biotechnology sector has been electrified by the announcement that Merck & Co. (NYSE: MRK) will acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in an all-cash...

Via Finterra

Topics Initial Public Offering Intellectual Property World Trade

Think Novo Nordisk Can't Keep Up in the GLP-1 Market? Its Latest Drug Approval Could Be a Game Changer ↗

March 24, 2026

The company recently obtained approval for a higher-dose version of Wegovy.

Via The Motley Fool

Institutional Titans Bet Big on Amgen as Dividend Yield Hits 2.9% Benchmark

March 23, 2026

In a decisive show of confidence for the biotechnology sector, institutional heavyweights have significantly ramped up their positions in Amgen (NASDAQ: AMGN) throughout the first quarter of 2026....

Via MarketMinute

Topics ETFs Earnings

Got $1,500? Is It Better to Buy Bitcoin, or Viking Therapeutics? ↗

March 22, 2026

One of these assets is catalyst-driven; the other isn't.

Via The Motley Fool

Topics Intellectual Property

Should You Buy Eli Lilly Stock Before April 10? ↗

March 22, 2026

A catalyst for stock performance may be just ahead.

Via The Motley Fool

Is This Stock a Buy on the Dip? ↗

March 21, 2026

This company has a habit of beating the market over long periods.

Via The Motley Fool

This Hims & Hers Move Could Destroy Competitors ↗

March 21, 2026

The Wegovy pill could change Hims & Hers' growth in 2026.

Via The Motley Fool

Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up? ↗

March 20, 2026

The healthcare stock has lost more than half of its value in the past year.

Via The Motley Fool

Is It Too Late to Buy Eli Lilly? ↗

March 19, 2026

Eli Lilly's GLP-1 drugs are leaders in a new and exciting drug category, but investors already know this fact.

Via The Motley Fool

Topics Intellectual Property

1 Reason I'm Never Selling Novo Nordisk Stock ↗

March 19, 2026

I am not turned off by the company's recent setbacks.

Via The Motley Fool

Hims & Hers (HIMS) 2026 Deep Dive: The $1.15B Eucalyptus Deal and the Branded Pivot

March 18, 2026

As of March 18, 2026, Hims & Hers Health (NYSE: HIMS) has reclaimed its position as the primary protagonist in the direct-to-consumer (DTC) healthcare narrative. Following a turbulent start to the year...

Via Finterra

Topics Intellectual Property

Hims & Hers Opens Up Pre-Launch Waitlist For Ozempic And Wegovy Following Partnership With Novo Nordisk ↗

March 18, 2026

The company stated that people who sign up for the waitlist will gain priority access to the official debut of Ozempic and Wegovy on the telehealth company’s platform.

Via Stocktwits

The Best Healthcare Stocks to Buy With $50 Right Now ↗

March 18, 2026

Even on a budget, you can get quality stocks.

Via The Motley Fool

Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics ↗

March 17, 2026

Each of these companies could benefit from this high-growth market over time.

Via The Motley Fool

Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise Move ↗

March 17, 2026

These companies are benefiting from a tidal wave of demand for new weight-loss drugs.

Via The Motley Fool

Topics Stocks

LLY Shares Dive On Analyst Downgrade Citing Obesity Market Overestimation Concerns, But Retail Dismisses ‘Absurd’ Selloff ↗

March 17, 2026

The analyst’s new price target represents a potential downside of about 14% from the stock’s last closing price on Monday.

Via Stocktwits

Why Eli Lilly Stock Just Dropped ↗

March 17, 2026

Eli Lilly's stock price is based on growth rates that might fall short.

Via The Motley Fool

This Promising GLP-1 Drug Could Give Novo Nordisk Investors Renewed Hope for the Stock ↗

March 17, 2026

Novo Nordisk recently announced promising trial results for one of its GLP-1 drugs in development.

Via The Motley Fool

Should You Avoid Pfizer? Here's the Key Risk to Watch ↗

March 17, 2026

Pfizer has reached a turning point.

Via The Motley Fool

Topics Intellectual Property

Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks ↗

March 16, 2026

The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.